Physician

Jason Tache, D.O.

According to 2025 Medicare claims, Jason Tache, D.O. (NPI: 1679561294) practices hematology/oncology in the Fort Lauderdale-Pompano Beach-Sunrise, FL market, with the plurality of this provider's patient population coming from Broward, FL. This provider's primary affiliated billing organization is SOUTH FLORIDA ONCOLOGY AND HEMATOLOGY CONSULTANTS LLC (NPI: 1700891256; TIN: 650577436) and primary practice location at 33322-5426.

Tache's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 348 traditional Medicare patients, billed 121,999 HCPCS/CPT codes, and received $1,713,852 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,245 prescription claims across 331 beneficiaries totaling $7,372,948 in drug costs, led by Lenalidomide (Lenalidomide). 2019 DME data shows 91 claims. Open Payments data shows 84 records totaling $143,583. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $1,013,934 and ending at $1,713,852. Concurrently, Part D prescription costs have risen steadily, from $2,888,871 to $7,372,948. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $1,591 and ending at $984.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	427	87,948	$1,013,934
2016	445	90,802	$939,768
2017	441	103,633	$1,119,000
2018	409	109,185	$1,248,939
2019	481	143,685	$1,268,183
2020	414	130,962	$1,891,048
2021	396	131,488	$1,403,237
2022	383	108,358	$1,008,858
2023	346	99,660	$1,110,383
2024	348	121,999	$1,713,852

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	263	1,920	$2,888,871
2016	255	2,045	$3,591,082
2017	275	2,154	$4,385,952
2018	289	1,965	$4,472,804
2019	318	2,068	$4,474,751
2020	304	1,908	$4,264,666
2021	303	1,950	$5,655,156
2022	291	2,073	$6,863,870
2023	323	2,175	$6,664,399
2024	331	2,245	$7,372,948

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	45	$1,072
2016	N/R	105	$3,408
2017	N/R	77	$13,549
2018	N/R	N/R	N/R
2019	N/R	91	$3,630
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	117	224	$101
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	67	200	$101
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	190	353	$74
36415	Insertion of needle into vein for collection of blood sample	56	71	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	270	1,092	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	50	1,400	$747,454
Jakafi	Ruxolitinib Phosphate	46	1,380	$736,984
Revlimid	Lenalidomide	35	980	$707,292
Promacta	Eltrombopag Olamine	22	660	$599,963
Qinlock	Ripretinib	11	330	$457,348

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	70	$1,188	E.R. Squibb & Sons, L.L.C.
Research Payments	Reported research-related payment or transfer-of-value amount.	14	$142,395	Novocure Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jason Tache, D.O.?

Tedicare shows public-source Medicare data for Jason Tache, D.O. (NPI 1679561294), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jason Tache, D.O. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Jason Tache, D.O.?

Jason Tache, D.O. is linked to SOUTH FLORIDA ONCOLOGY AND HEMATOLOGY CONSULTANTS LLC (billing NPI 1700891256) in the available physician profile data.

Does Jason Tache, D.O. have Open Payments data?

Jason Tache, D.O. has 84 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.